Madrigal Pharmaceuticals, Inc. (MDGL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Madrigal Pharmaceuticals, Inc. (MDGL) trades at $529.48 with AI Score 31/100 (Grade D). Madrigal Pharmaceuticals, Inc. Market cap: $12.21B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026MDGL stock analysis for 2026: Analysts have set a consensus price target of $767.50 for Madrigal Pharmaceuticals, Inc., suggesting 45.0% upside from the current price of $529.48. The AI MoonshotScore is 31/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MDGL: 1/1 perspectives are bearish.
How is this calculated? →Madrigal Pharmaceuticals, Inc. (MDGL) Healthcare & Pipeline Overview
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in therapies for liver, metabolic, and cardiovascular diseases, with a primary focus on resmetirom for NASH. The company's selective thyroid hormone receptor-ß agonist approach positions it uniquely within the competitive biotechnology landscape.
What Is the Investment Thesis for MDGL?
Madrigal Pharmaceuticals presents a notable research candidate centered on the potential approval and commercialization of resmetirom for NASH. The successful completion of Phase III clinical trials and subsequent regulatory approval could drive significant revenue growth. With a market capitalization of $12.21B, Madrigal's valuation is heavily dependent on the success of resmetirom. Key value drivers include positive clinical trial data, regulatory approval timelines, and market penetration in the NASH treatment landscape. The company's high gross margin of 93.1% suggests strong profitability potential upon commercialization. However, the negative beta of -1.01 indicates an inverse correlation with the market, which could be a risk during market upturns. Investors should closely monitor clinical trial results and regulatory milestones to assess the risk-reward profile.
Based on FMP financials and quantitative analysis
MDGL Key Highlights
- Market Cap of $12.21B reflects investor expectations for resmetirom's potential in the NASH market.
- Gross Margin of 93.1% indicates a strong potential for profitability upon commercialization of resmetirom.
- Profit Margin of -27.3% highlights the company's current investment in research and development.
- Lead product candidate, resmetirom, is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH).
- The company has a research, development, and commercialization agreement with Hoffmann-La Roche.
Who Are MDGL's Competitors?
MDGL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRNA Moderna, Inc. | $81.80 | +2.56% | 33B | — |
| JAZZ Jazz Pharmaceuticals plc | $244.17 | +0.29% | $15.34B | 58 |
| EXEL Exelixis, Inc. | $55.36 | -0.88% | $13.91B | 99 |
| BMRN BioMarin Pharmaceutical Inc. | $58.63 | -0.60% | $11.33B | 89 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDGL's Key Strengths?
- Lead product candidate, resmetirom, in Phase III clinical trials.
- Strong gross margin potential upon commercialization.
- Partnership with Hoffmann-La Roche.
- Proprietary drug development platform.
What Are MDGL's Weaknesses?
- Currently operating at a loss with a negative profit margin.
- Reliance on the success of a single lead product candidate.
- High R&D expenses.
- Negative beta indicates inverse market correlation.
What Could Drive MDGL Stock Higher?
- Completion of Phase III clinical trials for resmetirom.
- Regulatory submission and potential approval of resmetirom.
- Expansion of research and development efforts.
- Strategic partnerships and collaborations.
What Are the Key Risks for MDGL?
- Negative return on equity (-50.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 40.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Clinical trial failures or delays.
- Regulatory hurdles and approval delays.
- Competition from other companies developing NASH treatments.
- Adverse events or safety concerns related to resmetirom.
- Dependence on the success of a single lead product candidate.
What Are the Growth Opportunities for MDGL?
- Successful Commercialization of Resmetirom: The primary growth driver for Madrigal is the successful commercialization of resmetirom upon regulatory approval. The NASH market is estimated to reach billions of dollars in the coming years, offering a substantial revenue opportunity for Madrigal. The timeline for this growth is dependent on the completion of Phase III trials and subsequent regulatory review, expected within the next 1-2 years. Madrigal's competitive advantage lies in the potential efficacy and safety profile of resmetirom.
- Expansion into New Therapeutic Areas: Madrigal has the opportunity to leverage its expertise in liver and metabolic diseases to expand into new therapeutic areas. This could involve developing new drug candidates or acquiring existing assets. The market size for related metabolic diseases is significant, providing a long-term growth avenue for the company. This expansion could begin within the next 3-5 years, depending on the success of resmetirom and the company's strategic priorities.
- Partnerships and Collaborations: Madrigal can pursue strategic partnerships and collaborations to accelerate its research and development efforts. The existing agreement with Hoffmann-La Roche demonstrates the company's ability to attract partnerships with major pharmaceutical companies. These collaborations can provide access to funding, expertise, and commercialization resources. The timeline for new partnerships is ongoing, as Madrigal continues to explore opportunities to enhance its pipeline.
- Geographic Expansion: Madrigal has the potential to expand its geographic reach beyond the United States. The prevalence of NASH is increasing globally, creating opportunities to commercialize resmetirom in international markets. This expansion could involve establishing a direct sales force or partnering with local distributors. The timeline for geographic expansion is dependent on regulatory approvals in different countries, which could occur within the next 2-3 years.
- Development of MGL-3745: Madrigal's backup compound to resmetirom, MGL-3745, represents a potential growth opportunity. If resmetirom faces any setbacks or limitations, MGL-3745 could serve as an alternative treatment option. The development of MGL-3745 is currently in earlier stages, with a longer-term timeline for potential commercialization. This provides Madrigal with a degree of risk mitigation and a potential second product in the liver disease space.
What Opportunities Does MDGL Have?
- Successful commercialization of resmetirom in the NASH market.
- Expansion into new therapeutic areas.
- Strategic partnerships and collaborations.
- Geographic expansion into international markets.
What Threats Does MDGL Face?
- Clinical trial failures or delays.
- Regulatory hurdles and approval delays.
- Competition from other companies developing NASH treatments.
- Adverse events or safety concerns related to resmetirom.
What Are MDGL's Competitive Advantages?
- Proprietary drug development platform.
- Strong intellectual property protection for resmetirom.
- Advanced clinical development stage for lead product candidate.
- Established partnership with Hoffmann-La Roche.
What Does MDGL Do?
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of serious cardiometabolic and liver diseases. The company's primary focus is on non-alcoholic steatohepatitis (NASH), a liver disease with a high unmet medical need. Madrigal's lead product candidate, resmetirom, is a liver-directed, selective thyroid hormone receptor-ß agonist designed to improve liver function and reduce fibrosis in NASH patients. Resmetirom is currently in Phase III clinical trials, evaluating its safety and efficacy in a broad range of NASH patients. The company also develops MGL-3745, a backup compound to resmetirom. Madrigal was founded with the vision of addressing significant gaps in the treatment of liver and metabolic disorders. Through strategic research and development, the company has advanced resmetirom to late-stage clinical development, positioning itself as a potential leader in the NASH treatment landscape. Madrigal has a research, development, and commercialization agreement with Hoffmann-La Roche. Headquartered in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals continues to expand its research efforts and clinical programs to address the growing global burden of liver and metabolic diseases.
What Products and Services Does MDGL Offer?
- Develop therapeutic candidates for cardiovascular diseases.
- Develop therapeutic candidates for metabolic diseases.
- Develop therapeutic candidates for liver diseases.
- Focus on non-alcoholic steatohepatitis (NASH) treatment.
- Develop liver-directed selective thyroid hormone receptor-ß agonists.
- Conduct Phase III clinical trials for resmetirom.
How Does MDGL Make Money?
- Develop and commercialize pharmaceutical products.
- Generate revenue through sales of approved therapies.
- Partner with other pharmaceutical companies for research and commercialization.
- Focus on licensing and collaboration agreements.
What Industry Does MDGL Operate In?
Madrigal Pharmaceuticals operates within the biotechnology industry, specifically targeting the liver disease market. The NASH market is characterized by a high unmet medical need and a growing prevalence of the disease. The competitive landscape includes companies like Moderna, Inc. (MRNA) and Abivax S.A. (ABVX), which are also developing NASH treatments. The industry is driven by advancements in drug development and increasing awareness of liver diseases. Madrigal's selective thyroid hormone receptor-ß agonist approach positions it uniquely within this competitive environment.
Who Are MDGL's Key Customers?
- Patients with cardiovascular diseases.
- Patients with metabolic diseases.
- Patients with liver diseases, particularly NASH.
- Healthcare providers prescribing treatments for these conditions.
FY2026 estForward Outlook
Wall Street analysts project Madrigal Pharmaceuticals, Inc. revenue of about $1.49B for fiscal 2026, with EPS near $-7.21. The estimate reflects 11 contributing analysts.
F-Score 2/9Financial Health
Madrigal Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 9.18 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -50%Key Financial Metrics
Return on equity for Madrigal Pharmaceuticals, Inc. stands at -50.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.50 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.0%, the inverse of the P/E and a quick read on earnings relative to price.
Madrigal Pharmaceuticals, Inc. (MDGL) Valuation Context
Valued at $12.21B, MDGL is classified as a large-cap stock. Relative to its peer group, MDGL's quantitative score of 31/100 is below the peer average of 81/100.
Company Profile
Madrigal Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in West Conshohocken, US. The company is led by CEO William J. Sibold. MDGL has traded publicly since 2007.
MDGL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Lead product candidate, resmetirom, in Phase III clinical trials.
- Strong gross margin potential upon commercialization.
- Partnership with Hoffmann-La Roche.
- Proprietary drug development platform.
Bear Case
- Currently operating at a loss with a negative profit margin.
- Reliance on the success of a single lead product candidate.
- High R&D expenses.
- Negative beta indicates inverse market correlation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
MDGL Latest News
No recent news available for MDGL.
MDGL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDGL.
Price Targets
Consensus target: $767.50
MDGL MoonshotScore
What does this score mean?
The MoonshotScore rates MDGL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: William J. Sibold
CEO
William J. Sibold serves as the Chief Executive Officer of Madrigal Pharmaceuticals, Inc. He brings extensive experience in the pharmaceutical industry, with a proven track record of leading successful product launches and driving commercial growth. Prior to joining Madrigal, Mr. Sibold held leadership positions at various pharmaceutical companies, where he oversaw sales, marketing, and business development functions. His expertise spans multiple therapeutic areas, including cardiovascular, metabolic, and liver diseases. Mr. Sibold's background includes a strong focus on strategic planning, market access, and commercial execution.
Track Record: Under William J. Sibold's leadership, Madrigal Pharmaceuticals has advanced resmetirom to late-stage clinical development, positioning the company as a potential leader in the NASH treatment landscape. He has overseen the expansion of the company's research and development efforts, as well as the establishment of key partnerships. His strategic decisions have been instrumental in driving the company's growth and attracting investor interest.
Common Questions About MDGL (Healthcare)
What does Madrigal Pharmaceuticals, Inc. do?
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). The company aims to address the unmet medical needs in these therapeutic areas through innovative drug development and strategic partnerships.
What do analysts say about MDGL stock?
Analysts' outlook on Madrigal Pharmaceuticals is primarily focused on the potential of resmetirom in the NASH market. The stock's valuation is heavily influenced by the progress and outcome of Phase III clinical trials and the likelihood of regulatory approval. While some analysts are optimistic about resmetirom's potential, others remain cautious due to the inherent risks associated with drug development and regulatory processes. Investors should conduct their own due diligence and consider their risk tolerance before investing in MDGL.
What are the main risks for MDGL?
The main risks for Madrigal Pharmaceuticals include clinical trial failures or delays, regulatory hurdles and approval delays, competition from other companies developing NASH treatments, and adverse events or safety concerns related to resmetirom. The company's reliance on a single lead product candidate also poses a significant risk. Additionally, the biotechnology industry is subject to rapid technological advancements and changing regulatory landscapes, which could impact Madrigal's competitive position and future prospects.
What revenue streams does Madrigal Pharmaceuticals, Inc. have in healthcare?
Currently, Madrigal Pharmaceuticals does not have established revenue streams as it is a clinical-stage company. Its future revenue streams are contingent on the successful commercialization of resmetirom, which is in Phase III clinical trials for NASH. Upon regulatory approval, revenue would be generated through sales of resmetirom to healthcare providers and patients. The company may also explore licensing and collaboration agreements to generate additional revenue streams in the future.
What are the key growth opportunities for MDGL in healthcare?
Madrigal Pharmaceuticals' key growth opportunities lie in the successful commercialization of resmetirom for NASH, expansion into new therapeutic areas related to liver and metabolic diseases, strategic partnerships with other pharmaceutical companies, and geographic expansion into international markets. The company's expertise in liver-directed therapies and its advanced clinical development programs position it favorably to capitalize on these growth opportunities and address the unmet medical needs in the healthcare sector.
What are the key factors to evaluate for MDGL?
Madrigal Pharmaceuticals, Inc. (MDGL) holds an AI score of 31/100 (low). P/E: 40.2x vs the S&P 500's ~20-25x. Analysts target $767.50 (+45%). Not financial advice.
How frequently does MDGL data refresh on this page?
MDGL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven MDGL's recent stock price performance?
Madrigal Pharmaceuticals, Inc. (MDGL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product candidate, resmetirom, in Phase III clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial circumstances.